[MigVax in CEPI] CEPI announces first funding awards in quest to develop ‘variant-proof’ COVID-19 vaccines

CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the first funding awards under its $200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses [1]. CEPI will support researchers at two institutions, MigVax Ltd, Israel, and the University of Saskatchewan’s (USask) Vaccine and Infectious Disease Organization (VIDO), Canada, as they seek to establish preclinical proof of concept for novel vaccines suitable for use in low-and middle-income countries that are broadly protective against COVID-19 variants.

Read more here.

Source: https://blog.ourcrowd.com/cepi-announces-first-funding-awards-in-quest-to-develop-variant-proof-covid-19-vaccines/